Data last refreshed November 16th, 2026Prices and terms were read from each provider’s own site on that date and change often, sometimes weekly. Re-checked twice a month; next refresh due December 1st, 2026.
Tirzepatide providers: what a month really costs
Tirzepatide is a legal, approved medicine, so the question is not whether a seller is real. It is what you will actually pay once the introductory rate ends. All 1 providers here publish what a 10 mg maintenance dose costs.
Evo does not sell medication and has no commercial relationship with anyone listed here. There are no affiliate links on this page and no provider paid to appear. That matters more in this market than most: clicks on these searches sell for $30 to $46, and most of the competing “cheapest provider” guides are paid by commission.
Tirzepatide provider comparison
We publish the raw data. Every figure was read from the provider’s own site, with the source recorded — prices, fees, commitment terms, what is in the syringe, and how each rating was calculated. Download the full capture (JSON) and check any row, or re-weight the rating to suit your own priorities.
1 online tirzepatide providers with Evo Rating, real monthly cost at a maintenance dose, what is in the syringe and provider type, captured November 16th, 2026.
A dash means the provider does not publish it, not that we did not look — the text under each dash says why. We checked for a machine-readable price on every one of them (Shopify product data, the WooCommerce store API, embedded page data) and not a single provider exposes one, because here the price is the thing you trade your medical history for. “Real cost at 10 mg” is the all-in monthly figure: medication plus any mandatory membership, adjusted for how many times a year you are actually billed. 0 providers do not say what is in their product at all, which caps their rating at 2.5however cheap they are. Every provider the FDA has written to about its tirzepatide marketing has been removed from the table entirely — they are listed under what we excluded, below.
What each rating is made of
Every point below comes from something published on the provider’s own site. Nothing is an editorial impression, and no rating is entered by hand.
Ro
2.32.34 out of 5 stars
✓Real monthly cost +0.4 About $562 a month all in at 10 mg, including the Ro Body membership.
✓What is in the syringe +1.5 The FDA-approved drug, with nothing added.
✓Easy to leave +0.1875 Offers cancel without a phone call. Does not: refunds unused prepaid months, price held as the dose escalates, advertised rate without prepaying a block.
✓Price published up front +0.25 Prices are readable without starting an intake questionnaire.
Starting dose: Zepbound KwikPen cash-pay rate. Membership is separate: $39 for the first month, then $74/month only with annual prepayment; the ongoing monthly plan is $149/month.
At maintenance: 10 mg Zepbound KwikPen with the manufacturer offer: $449 per four-week supply, plus annually prepaid membership. Complete the next refill check-in within 45 days of the last delivery or the 10 mg refill costs $699. Cash pay only, outside insurance; prescription and eligibility required.
Commitment: the advertised rate needs 12 months.
The $74/month membership requires a 12-month prepaid plan. Membership payments are non-refundable once paid. Cancel online at least 48 hours before renewal; access continues through the paid billing cycle.
How this page was built
Which providers are listed. We measured who is actually visible rather than picking names. Six buying-intent Google queries — “cheapest tirzepatide”, “buy tirzepatide online”, “compounded tirzepatide”, “tirzepatide without insurance”, “where to buy tirzepatide” and “tirzepatide for sale” — were pulled through a rank-tracking API, and every commerce domain in those results was recorded. Editorial and affiliate roundups were discarded; only providers that actually sell or prescribe are in the table.
Where the numbers come from. A scraper reads each provider’s own pricing page for prices with the sentences around them, because a bare figure is useless here — whether $299 is per month, per quarter or per starting dose is the entire question. Every figure was then confirmed by hand, and several pages had to be read in a browser because they refuse automated requests. Anything still unestablished is blank.
What we could not get. Where a price is blank, the row says why. Providers that hide a maintenance price usually do so behind an intake questionnaire, which we did not complete: filling in a medical history to extract a price would mean submitting false information, and we are not going to do that to write a table. Where a price could be found by digging — a separate pricing page, a titration schedule, a footnote — we dug, and several rows that were blank on the first pass now carry a figure.
The FDA letters. There are 109 warning letters naming tirzepatide, and 85 of the 100 most recent target telehealth companies — for misleading claims or for selling unapproved drugs online. Forty were issued in 2025 and sixty more in 2026. Any provider named in one is removed from this table rather than flagged in it: a capped rating still puts a company in front of you as an option, and these are the companies the agency has actually looked at.
Finding them takes a particular route, because the index does not search letter bodies and a domain query returns nothing. We queried the compound instead, then opened each candidate letter and confirmed the website it names before excluding anyone on that basis. 4 providers came out that way.
What we removed. Every provider the FDA has written to about its tirzepatide marketing, providers outside the United States, sites that could not be reached at all, one that advertises GLP-1 treatment but sells no tirzepatide, and one selling it as a laboratory reagent rather than for human use:
fifty410.com — FDA warning letter, 20 February 2026, over claims for its compounded semaglutide and tirzepatide. The letter names fifty410.com. Read the letter.
ivimhealth.com — FDA warning letter, 20 February 2026, over claims for its compounded semaglutide and tirzepatide. The letter names ivimhealth.com. Read the letter.
remedymeds.com — FDA warning letter, 9 September 2025, over claims concerning its compounded semaglutide and tirzepatide. The letter names remedymeds.com. Read the letter.
tryeden.com — FDA warning letter, 8 June 2026, over its website's claims for compounded semaglutide and tirzepatide. The letter names tryeden.com. Read the letter.
medvi.com — FDA warning letter, 20 February 2026. Considered as a replacement and rejected for the same reason.
israelpharm.com — Ships from outside the United States, so a different regulatory regime applies.
henrymeds.com — Advertises GLP-1 treatment from $179/month but no tirzepatide product could be found on the site.
mochihealth.com — Site could not be reached from here at capture.
zealthy.com — Site could not be reached from here at capture.
adipogen.com — Sells tirzepatide as a laboratory reagent, not for human use.
What this page cannot tell you. Nothing here is a judgement of clinical care — we have not seen a consultation, and a cheap provider with a good rating may still be the wrong choice for you. Prices are promotional and move constantly. And a rating is a weighted opinion about which trade-offs matter: ours puts cost first and contents second, which may not be your order. The raw data exists so you can use your own.
Questions people ask
Answered from the FDA’s own statements, published research, and what we captured from the providers themselves. Where the honest answer is that nobody publishes it, it says so.
How does tirzepatide work?
Tirzepatide is a single molecule that activates two receptors: GIP and GLP-1. That dual action is what separates it from semaglutide, which acts on GLP-1 alone. It slows how quickly the stomach empties, acts on the appetite centres of the brain, and improves the insulin response after eating.
It is given as a once-weekly injection under the skin, and the dose is escalated gradually over months because side effects track the dose closely. Unlike most of what this site covers, tirzepatide is an approved medicine with published Phase 3 trials behind it — sold as Zepbound for weight management and Mounjaro for type 2 diabetes.
What does tirzepatide actually cost per month?
That is the question this page exists to answer. All 1 providers here publish what a 10 mg maintenance dose costs.
No verified compounded or manufacturer self-pay maintenance price is in this capture; the table shows the prices that were verified.
Three things can move the real number a long way from the advertised one. A mandatory membership fee may be quoted separately from the medication. A 'monthly' price may mean a quarter or half-year paid up front. And the billing period may not be a calendar month at all — a 28-day cycle bills about thirteen times a year. The table's monthly figure accounts for all three where they are published.
Is compounded tirzepatide legal?
The legal footing it once had has gone. Mass compounding of tirzepatide was permitted because the drug was in shortage; the FDA declared that shortage resolved on 2 October 2024, and with it the basis for compounding copies.
Providers continue to sell it by not selling a copy. A pharmacy may not compound something that is essentially a copy of an approved drug, so products are sold as tirzepatide combined with a vitamin — B12, B6, niacinamide — and marketed as 'personalized'. The additive is there for a legal reason rather than a clinical one.
This is a description of how the market is regulated and not legal advice. It is also moving: the position stated here is as of the capture date at the top of this page.
Is compounded tirzepatide the same as Zepbound or Mounjaro?
No. Compounded products are not FDA-approved, are not made to the same manufacturing standards, and in most cases are not the same molecule in the syringe — because of the vitamin they are mixed with.
A 2026 paper in Expert Opinion on Drug Safety tested compounded tirzepatide/B12 products and reported a previously unidentified impurity, present at substantial levels, formed by a chemical reaction between tirzepatide and certain B12 analogs. The clinical effect of that impurity is unknown.
One caveat matters as much as the finding: every author of that paper works for Eli Lilly, which holds the patent and sells the competing approved product. It is peer-reviewed and the chemistry is checkable, but it has not been independently replicated, and the loudest safety voice in this market being the patent holder is part of the picture. We have weighted the B12 combination accordingly in the rating rather than treating all compounding as equivalent.
What happened to the providers with FDA warning letters?
They are not in the table. There are 109 FDA warning letters naming tirzepatide, and 85 of the 100 most recent target telehealth companies — for false or misleading claims, or for selling unapproved and misbranded drugs online. Forty were issued in 2025 and sixty more in 2026, so this is an active sweep rather than a historical footnote.
4 providers were removed on that basis and are listed under what we excluded, with a link to each letter. They are removed rather than flagged and left in because a low price next to a warning badge still reads as an option.
The absence of a letter is not a clean bill of health. It means the agency has not published one naming that company over tirzepatide, and plenty of sellers have simply not been reviewed yet.
Is the approved drug more expensive than compounded?
No verified compounded or manufacturer self-pay maintenance price is in this capture; the table shows the prices that were verified.
Compare all-in maintenance figures rather than headline prices. Advertised compounded prices can exclude a mandatory membership, assume a prepaid block, or quote the 2.5 mg starting dose rather than a maintenance dose.
Whether the approved drug is worth any difference is your call, not ours. What this page can do is make the verified numbers comparable.
What does the Evo Rating measure?
Three things, weighted: what a month really costs at a maintenance dose (2.0 points), what is actually in the syringe (1.5), how easy the provider is to leave (1.0), and whether the price is published before you hand over your medical history (0.5).
It is deliberately not the Evo Trust Score used on our retatrutide and BPC-157 tables. Those score whether a seller's claims can be verified at all, which is the right question in a market with no legal channel. Here you can buy an approved drug with a prescription, so the open questions are cost, contents and friction. A 4 on this page and a 4 on those pages do not mean the same thing.
Every component and its reasoning is published in the raw data, so if you think price should count for more than we gave it, you can recompute the whole table rather than just disagree with it.
Does Evo sell tirzepatide or earn commission from these providers?
No. Evo does not sell medication, has no commercial relationship with any provider listed, and takes nothing from anyone on this page. There are no affiliate links here and no provider paid to appear.
That is worth stating plainly in this market in particular. Clicks on these terms sell for $30 to $46, and most of the competing 'cheapest provider' roundups are monetised by affiliate commission. The full capture behind this table is published as JSON so you can check any row rather than trust ours.
Related
Our tirzepatide calculator works out concentration and syringe units from a vial, presenting ranges and assumptions rather than recommendations. We keep comparable tables for retatrutide and BPC-157 — both unapproved compounds, both scored on verifiability rather than on price, and neither number comparable with the ratings above.